Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arcus Biosciences (RCUS) EBITDA (2017 - 2025)

Historic EBITDA for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to -$142.0 million.

  • Arcus Biosciences' EBITDA fell 3523.81% to -$142.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$375.0 million, marking a year-over-year decrease of 1792.45%. This contributed to the annual value of -$330.0 million for FY2024, which is 294.12% up from last year.
  • According to the latest figures from Q3 2025, Arcus Biosciences' EBITDA is -$142.0 million, which was down 3523.81% from -$8.0 million recorded in Q2 2025.
  • Arcus Biosciences' 5-year EBITDA high stood at $278.2 million for Q4 2021, and its period low was -$142.0 million during Q3 2025.
  • Its 5-year average for EBITDA is -$61.7 million, with a median of -$78.0 million in 2021.
  • Within the past 5 years, the most significant YoY rise in Arcus Biosciences' EBITDA was 63613.22% (2021), while the steepest drop was 453553.16% (2021).
  • Arcus Biosciences' EBITDA (Quarter) stood at $278.2 million in 2021, then crashed by 126.6% to -$74.0 million in 2022, then decreased by 22.97% to -$91.0 million in 2023, then fell by 13.19% to -$103.0 million in 2024, then crashed by 37.86% to -$142.0 million in 2025.
  • Its EBITDA was -$142.0 million in Q3 2025, compared to -$8.0 million in Q2 2025 and -$122.0 million in Q1 2025.